Clinical Trial Update: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

NRG Oncology is conducting a Phase 3 trial of doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin for triple-negat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: NRG Oncology | Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative | Phase 3 | Status: ACTIVE_NOT_RECRUITING